Furthermore, we found that TCF12 depletion sensitizes melanoma cells to BRAF inhibition, suggesting that TCF12 may represent a potential therapeutic target for enhancing the efficacy of current BRAF-targeted therapies. The gene discussed is BRAF; the disease is melanoma.